Portal de investigação
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Dados básicos
- Código:
- Ensaio Clínico Académico (SOGALDI-PEF)
- Protocolo:
- Ensaio Clínico Académico (SOGALDI-PEF)
- EUDRACT:
- 020-000973-26
- NCT:
- NCT05676684
- Centro:
- Dotação:
- Ano de início:
- 2022
- Ano de conclusão:
- 2024
Objectivos do projeto
Ensaio Clínico - Iniciativa do Investigador; Fase: II – Aleatorizado e Controlado; Subtipo: Tratamento – Medicamento; Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Multicêntrico – 2 Centros de Cuidados Secundários – Centros de Ensaio: CHUSJ/CHVNGE; Doença investigada: Insuficiência cardíaca – Participantes recrutados: 86
Documentos
- Não há documentos
Participantes
-
Francisco Aguiar Vasques Novoa Faria
Investigador Colaborador
-
Joaquim Adelino Correia Ferreira Leite Moreira
Sub-Investigador
-
Ricardo Manuel Alves Monteiro Fontes De Carvalho
Sub-Investigador
-
Francisca Almeida Saraiva
Investigador Colaborador
-
João Pedro Melo Marques Pinho Ferreira
Investigador Principal
Unidades de investigação
-
RISE-Health
Investigador
Fernando Carlos De Landér Schmitt
Stakeholders - Promotores
Outputs do ensaio clínico
Automatic Contrast Generation from Contrastless Computed Tomography
Domingues, Ruben; (...); Renna, Francesco
Proceedings Paper. 10.1109/EMBC40787.2023.10340695. 2023
Glucose utilization by the trained heart: the molecular mechanisms behind fuel choice
Nogueira-Ferreira R.; (...); Ferreira R.
Book Chapter. 10.1016/B978-0-323-91704-9.00015-X. 2023
Glycolysis in pulmonary arterial hypertension and metabolic reprogramming
Vasconcelos I.; (...); Adão R.
Book Chapter. 10.1016/B978-0-323-91704-9.00008-2. 2023
Heart failure: pathophysiology and the emergence of novel therapies
Silva-Cardoso J.; (...); Leite-Moreira A.
Book Chapter. 10.1016/B978-0-323-99991-5.00016-4. 2023
LoRaWAN Based Street Lighting for Remote Areas with Shadow Zones
Ferreira, Joao; (...); Agreira, C. I. Faustino
Proceedings Paper. 10.1109/MELECON56669.2024.10608473. 2024
Pancreatic ß cells: the metabolic network underlying body’s glucostat
Ferreira R.; (...); Neves J.S.
Book Chapter. 10.1016/B978-0-323-91704-9.00005-7. 2023
Useful bioinformatics approaches for studying pathological conditions characterized by the dysregulation of glucose metabolism
Reumiller C.M.; (...); Trindade F.
Book Chapter. 10.1016/B978-0-323-91704-9.00003-3. 2023
?UFO: Unidentified Flying Object in the Heart?: An Unusual Sighting of a Cardiac Calcified Amorphous Tumour
Ribeiro Silva, M; (...); Fontes Carvalho, R.
Article. 10.4250/jcvi.2022.0139. 2023
2022 Year in Review
Sorgente, A; (...); Enriquez-Sarano, ML
Article. 10.1016/j.jaccas.2022.101727. 2023
A 4-variable model to predict cardio-kidney events and mortality in chronic kidney disease: The Chronic Renal Insufficiency Cohort (CRIC) Study
Mendon?a, L.; (...); Ferreira, J.
Article. 10.1159/000533223. 2023
A 4-variable model to predict cardio-kidney events and mortality in chronic kidney disease: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Mendonça, LCF; (...); Ferreira, JP
Article. 2023
A challenging case of prosthetic mitral valve dysfunction: the value of multimodality imaging
Duarte, F; (...); Fontes-Carvalho, R
Editorial Material. 10.1007/s10554-023-03028-0. 2023
A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial
Kobayashi, M; (...); Girerd, N
Article. 10.1002/ejhf.2859. 2023
A meta-analysis of randomized controlled studies comparing off-pump vs on-pump CABG in the elderly
Machado, RJ; (...); Leite-Moreira, AF
Meeting Abstract. 2021
A prospective study on varicose veins surgery impact on systemic endothelial function evaluated by arterial brachial flow mediated dilation
Nóbrega, L; (...); Castro-Ferreira, R
Article. 10.1177/17085381231175707. 2023
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19
Sharma, A; (...); Ferreira, JP
Article. 10.1016/j.ahj.2022.01.015. 2022
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.
Sharma, A; (...); Ferreira, JP
Article. 2022
A Starr-Edwards Prosthesis Can Last Forever (But Its Sutures May Not)
Nunes, Fabio Sousa; (...); Neves, Fatima Sousa
Editorial Material. 10.1016/j.hjc.2024.03.011. 2024
A systematic review and meta-analysis of randomized controlled studies comparing off-pump versus on-pump coronary artery bypass grafting in the elderly
Machado, RJ; (...); Leite Moreira, AF
Review. 10.23736/S0021-9509.21.12012. 2022
Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
de Sá, J, Ferreira, J, Macedo, AM
Article. 10.33588/rn.76S01.2022296. 2023
Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction
Moreira-Costa L.; (...); Lourenço A.P.
Article. 10.1016/j.ejphar.2024.176336. 2024
Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction.
Moreira-Costa, L; (...); Lourenço, AP
Article. 2024
Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure
Kobayashi M.; (...); Ferreira J.P.
Article. 10.1016/j.ijcard.2024.132477. 2024
Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes
Ferreira, J.; (...); Neves, J.
Article. 10.1002/ejhf.2660. 2022
Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.
Ferreira, JP; (...); Neves, JS
Article. 2022
An Analysis From a Tertiary Pediatric Hospital: Does Physical Activity Play a Role in the Management of Children and Young Adults With Osteogenesis Imperfecta?
Saraiva, Francisca Galhardo; (...); Campagnolo, Joao Lameiras
Article. 10.7759/cureus.53646. 2024
Aortic stenosis progression among patients with bicuspid aortic valve
Teixeira, R.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Aortic stenosis rapid progression is associated with premature cardiac damage independently of baseline severity
Teixeira, R; (...); Fontes-Carvalho, R
Meeting Abstract. 2023
Aortic Valve Surgery in Patients with Infective Endocarditis: Mid-Term Follow-up of Patients Treated With the ST. Jude Medical Trifecta Valve.
Silva B; (...); Leite-Moreira A
Article. 10.48729/pjctvs.283. 2022
Artificial intelligence and colon capsule endoscopy: Automatic detection of ulcers and erosions using a convolutional neural network
Ribeiro, T; (...); Macedo, G.
Article. 10.1111/jgh.16011. 2022
Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: an analysis from the Swedish Heart Failure Registry
Schrage, B; (...); Savarese, G
Article. 10.1002/ejhf.2928. 2023
Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry.
Schrage, B; (...); Savarese, G
Article. 2023
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure A Secondary Analysis of EMPEROR-Pooled
Ferreira, JP; (...); Packer, M
Article. 10.1001/jamacardio.2022.2924. 2022
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure A Secondary Analysis of EMPEROR-Pooled. - A Secondary Analysis of EMPEROR-Pooled.
Ferreira, JP; (...); Packer, M
Article. 2022
Association of metabolic syndrome components and NAFLD with quality of life: Insights from a cross-sectional study
Borges-Canha M.; (...); Neves J.S.
Article. 10.1016/j.pcd.2024.01.004. 2024
Association of thyroid function, within the euthyroid range, with cardiovascular risk: The EPIPorto study
Neves, J.; (...); Azevedo, A.
Article. 10.3389/fendo.2022.1067801. 2022
Authors reply in response to a letter on "Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study"
Roncon Albuquerque, R.; (...); Paiva, JA
Letter. 10.1186/s13613-023-01215-9. 2023
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
Ravassa, S; (...); González, A
Article. 10.1002/ejhf.2394. 2022
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Pocock, SJ; (...); Anker, SD
Article. 10.1002/ejhf.2607. 2022
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Pocock, SJ; (...); Anker, SD
Article. 2022
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
Packer, M; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.123.065748. 2023
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
Packer, M; (...); Anker, SD
Article. 2023
Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial
Ferreira, J.; (...); Zannad, F
Article. 10.1159/000519436. 2022
Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial.
Ferreira, JP; (...); Zannad, F
Article. 2022
Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial
Sattar N.; (...); Anker S.D.
Article. 10.1002/ejhf.3221. 2024
Body mass index effect on long-term survival after coronary artery bypass surgery: a competing risk analysis
Abreu, A; (...); Leite-Moreira, A
Article. 10.1093/icvts/ivad161. 2023
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial
Ferreira, J.; (...); Zannad, F
Article. 10.1186/s12933-021-01382-8. 2021
Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review
Figueiredo, R; (...); Brás-Silva, C
Review. 10.1016/j.repc.2021.03.020. 2022
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme
Ferreira, JP; (...); Januzzi, JL
Article. 10.1002/ejhf.3166. 2024
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial
Sharma, A; (...); Anker, SD
Article. 10.1002/ejhf.2857. 2023
Cardiac Remodeling and Diastolic Dysfunction in Paroxysmal Atrial Fibrillation
Noirclerc, N; (...); Girerd, N
Article. 10.3390/jcm10173894. 2021
Cardiac remodelling and reverse remodelling in pregnant women: what can be expected?
Ferreira, AF; (...); Fa, I
Meeting Abstract. 2021
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Colombo G.; (...); Inciardi R.M.
Review. 10.1002/ehf2.15095. 2024
Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.ijcard.2022.01.053. 2022
Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas.
Ferreira, JP; (...); Zannad, F
Article. 2022
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
Ferreira, J.; (...); Zannad, F
Article. 10.1161/JAHA.120.020053. 2021
Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF
Sharma, A; (...); Zannad, F
Article. 10.1136/bmjopen-2022-068865. 2023
Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
Sharma, A; (...); Zannad, F
Article. 2023
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
Neves J.S.; (...); Ferreira J.P.
Article. 10.1002/ejhf.3478. 2024
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
Razaghizad, A; (...); Sharma, A
Article. 10.1111/dom.15768. 2024
Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed
Ferreir, Joao Pedro, Neves, Joao Sergio, Saraiva, Francisca
Editorial Material. 10.1016/j.cardfail.2023.12.002. 2024
Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed.
Ferreira, JP, Neves, JS, Saraiva, F
Article. 2024
Cardiovascular remodelling and reverse remodelling during pregnancy and postpartum: Looking at the right side
Ferreira A.F.; (...); Falcão-Pires I.
Article. 10.1016/j.preghy.2024.101171. 2024
Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling
Ferreira, AF; (...); Falcao-Marques, I
Article. 10.1152/ajpheart.00200.2023. 2023
Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling (vol 325, pg H774, 2023)
Ferreira, Ana Filipa; (...); Falcao-Pires, Ines
Correction. 10.1152/ajpheart.00200.2023_COR. 2024
Catastrophic presentation of peripartum cardiomyopathy: a case report of a challenging diagnosis
Silva, MR; (...); Fontes Carvalho, R.
Article. 10.1093/ehjcr/ytac395. 2022
Catheter ablation for atypical atrial flutter: characterization and recurrence predictors
Barradas, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis
Kobayashi, M; (...); Ferreira, J.
Article. 10.3389/fcvm.2021.754784. 2021
Circulating levels of procollagen type I carboxy-terminal propeptide reflect myocardial fibrosis
Ferreira, J.
Editorial Material. 10.1002/ejhf.2216. 2021
Clinical and Pathophysiologic Insights of Free triiodothyronine/Free thyroxine Ratio in Patients with Heart Failure with Preserved Ejection Fraction: Data from the NETDiamond Cohort
Leite, AR; (...); Leite-Moreira, A
Article. 10.1159/000530136. 2023
Clinical and Pathophysiologic Insights of Free triiodothyronine/Free thyroxine Ratio in Patients with Heart Failure with Preserved Ejection Fraction: Data from the NETDiamond Cohort.
Leite, AR; (...); Leite Moreira, A
Article. 2023
Clinical associations and prognostic implications of 6-minute walk test in rheumatoid arthritis
Ferreira, MB; (...); Ferreira, JP
Article. 10.1038/s41598-022-21547-z. 2022
Clinical associations and prognostic implications of 6-minute walk test in rheumatoid arthritis.
Ferreira, MB; (...); Ferreira, JP
Article. 2022
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF
Shen L.; (...); McMurray J.J.V.
Article. 10.1161/CIRCULATIONAHA.124.070553. 2024
Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis
Razaghizad, A; (...); Sharma, A
Review. 10.1161/JAHA.121.024833. 2022
Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Razaghizad, A; (...); Sharma, A
Review. 2022
Clinical relevance of the blanking period on late recurrence after catheter ablation of atrial fibrillation
Silva, MR; (...); Fontes Carvalho, R.
Article. 10.1111/jce.15729. 2023
Clinical relevance of the blanking period on late recurrence after catheter ablation of atrial fibrillation.
Silva, MR; (...); Fontes Carvalho, R
Article. 2023
Combined central and peripheral demyelination after COVID-19 vaccination
Coelho, P; (...); Albuquerque, L
Letter. 10.1007/s00415-022-11188-7. 2022
Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study
Ferreira J.P.; (...); Leite-Moreira A.
Article. 10.1016/j.atherosclerosis.2024.117461. 2024
Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study.
Ferreira, JP; (...); Leite-Moreira, A
Article. 2024
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
Carson, P; (...); Packer, M
Article. 10.1016/j.jchf.2022.11.017. 2023
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial.
Carson, P; (...); Packer, M
Article. 2023
Comprehensive characterization of protein modifications using mass spectrometry and dry blood spots
Guedes, S; (...); Vitorino, R.
Article. 10.1002/prca.202300102. 2024
Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial
Packer, M; (...); Zannad, F
Article. 10.1002/ejhf.2256. 2021
Concomitant left atrial and left ventricular masses: lessons to clinical practice
Brandao, M; (...); Fontes-Carvalho, R
Article. 10.1093/ehjci/jeac236. 2022
Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement: Feasibility in clinical practice
Silva, G; (...); Fontes-Carvalho, R
Article. 10.1016/j.repc.2022.10.012. 2023
Coronary Artery Disease and Aortic Valve Stenosis: A Urine Proteomics Study
Perpetuo, L; (...); Vitorino, R.
Article. 10.3390/ijms232113579. 2022
Corrigendum: Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis(Front. Cardiovasc. Med., (2024), 11, (1407566), 10.3389/fcvm.2024.1407566)
Sousa Nunes F.; (...); Sousa C.
Correction. 10.3389/fcvm.2024.1471225. 2024
Corticotropin-releasing hormone and obesity: From fetal life to adulthood
Vasconcelos I.; (...); Brás-Silva C.
Review. 10.1111/obr.13763. 2024
Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design
Pellicori, P; (...); Sanyal, AJ
Review. 10.1016/j.diabet.2021.101281. 2022
Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design.
Pellicori, P; (...); Sanyal, AJ
Review. 2022
Current clinical use of speckle-tracking strain imaging: insights from a worldwide survey from the European Association of Cardiovascular Imaging (EACVI)
Sade, LE; (...); Dweck, MR
Article. 10.1093/ehjci/jead170. 2023
Current role and future perspectives of artificial intelligence in echocardiography
Vidal-Perez, R; (...); Vazquez-Rodriguez, JM
Review. 10.4330/wjc.v15.i6.284. 2023
Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis
Angelico Goncalves, A; (...); Ferreira, J.
Article. 10.1016/j.ijcard.2023.05.032. 2023
Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis.
Angelico Goncalves, A; (...); Ferreira, JP
Article. 2023
DEEP LEARNING AND DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY (DSOC): AUTOMATIC DIAGNOSIS OF MALIGNANCY STATUS AND MORPHOLOGICAL CHARACTERIZATION OF BILIARY STRICTURES.
Saraiva, MM; (...); Macedo, G
Meeting Abstract. 2022
Dependability evaluation and sensitivity analysis of data center cooling systems
Souza, Lubnnia; (...); Ferreira, Joao
Article. 10.1007/s11227-023-05419-5. 2023
Detailed safety analysis of DIAMOND trial: 'primum non nocere'?
Baptista, R, Gonçalves, S, Fontes-Carvalho, R
Editorial Material. 10.1093/eurheartj/ehad473. 2023
DEVELOPMENT OF A CONVOLUTIONAL NEURAL NETWORK FOR AUTOMATIC DETECTION AND PHENOTYPIC DIFFERENTIATION OF PANCREATIC CYSTIC LESIONS
Ribeiro, TF; (...); Macedo, G
Meeting Abstract. 2022
Differences in biomarkers and molecular pathways according to age for patients with HFrEF
Ferreira, J.; (...); Zannad, F
Article. 10.1093/cvr/cvaa279. 2021
Digital flashcards and medical physiology performance: a dose-dependent effect
Santos-Ferreira D.; (...); Leite-Moreira A.
Article. 10.1152/advan.00138.2023. 2024
Digital flashcards and medical physiology performance: a dose-dependent effect.
Santos Ferreira, D; (...); Leite Moreira, A
Article. 2024
Digital follow-up program for patients undergoing atrial fibrillation ablation: a pilot single-center study
Brandao, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Digital health and cardiovascular healthcare professionals in Portugal: Current status, expectations and barriers to implementation
Queiroz, Carlota; (...); Ladeiras-Lopes, Ricardo
Article. 10.1016/j.repc.2023.10.014. 2024
Digitisation of patient preferences in palliative care: mobile app prototype
Ferreira, J; (...); Campos, MJ
Article. 10.1136/spcare-2023-004516. 2023
DISSECTING SEXUAL DIMORPHISM IN AORTIC VALVE STENOSIS BY PROTEOMICS
Grego, Ana; (...); Trindade, Fabio
Meeting Abstract. 2024
Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
Ferreira J.P., MENDONÇA L.U.Í.S., NEVES J.S.
Article. 10.1016/j.cardfail.2024.05.006. 2024
Door-to-furosemide time and clinical outcomes in acute heart failure
Marques, P; (...); Frioes, F
Article. 10.1097/MEJ.0000000000001006. 2023
Door-to-furosemide time and clinical outcomes in acute heart failure
Brito, MT; (...); Marques, P
Meeting Abstract. 2022
Door-to-furosemide time and clinical outcomes in acute heart failure.
Marques, P; (...); Frioes, F
Article. 2023
Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial
Ferreira, J.; (...); Zannad, FAB -
Article. 10.1002/ejhf.2255. 2021
Doxorubicin-induced cardiotoxicity - Are plants the answer?
Mendes-Ferreira P, Leite-Moreira AF
Article. 10.1016/j.repc.2024.10.003. 2024
Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial.
Monzo, L; (...); Zannad, F
Article. 2022
Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial
Monzo, L; (...); Zannad, F
Article. 10.1002/ehf2.14086. 2022
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial
Ferreira, JP; (...); Rossignol, P
Letter. 10.1007/s00392-022-02116-w. 2023
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
Butler, J; (...); Anker, SD
Editorial Material. 10.1002/ejhf.2420. 2022
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved
Rastogi, T; (...); Zannad, F
Article. 10.1002/ejhf.3136. 2024
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced
Zannad, F; (...); Packer, M
Article. 10.1002/ejhf.2578. 2022
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
Zannad, F; (...); Packer, M
Article. 2022
Early-onset atherosclerosis in a patient with Tangier disease: Not all that is gold glitters
Silva, G; (...); Fontes-Carvalho, R
Editorial Material. 10.33963/KP.a2023.0061. 2023
Echocardiographic assessment of the right heart in patients with aortic stenosis undergoing transcatheter aortic valve implantation: analysis from a large single-center cohort
Brandao, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
Butler, J; (...); Anker, SD
Article. 10.1093/eurheartj/ehab798. 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
Zannad, F; (...); Packer, M
Article. 10.1093/eurheartj/ehac495. 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.
Zannad, F; (...); Packer, M
Article. 2022
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
Packer, M; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.121.056824. 2021
Effect of eplerenone on clinical stability of Japanese patients with acute heart failure
Kobayashi, M; (...); Kitakaze, M
Article. 10.1016/j.ijcard.2022.12.045. 2023
Effect of eplerenone on clinical stability of Japanese patients with acute heart failure.
Kobayashi, M; (...); Kitakaze, M
Article. 2023
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials
Leite, AR; (...); Ferreira, J.
Article. 10.1111/dom.14707. 2022
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
Leite, AR; (...); Ferreira, JP
Article. 2022
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
Dewan P.; (...); McMurray J.J.V.
Article. 10.1161/CIRCULATIONAHA.124.068774. 2024
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.amjcard.2022.12.016. 2023
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Ferreira, JP; (...); Zannad, F
Article. 2023
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
Butler, J; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.122.059755. 2022
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
Butler, J; (...); Anker, SD
Article. 2022
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced
Filippatos, G; (...); Packer, M
Article. 10.1002/ejhf.2707. 2022
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.
Filippatos, G; (...); Packer, M
Article. 2022
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.3101. 2023
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
Kosiborod, MN; (...); Voors, AA
Article. 10.1161/CIRCULATIONAHA.122.059725. 2022
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Kosiborod, MN; (...); Voors, AA
Article. 2022
Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial
Ferreira, JP; (...); Wanner, C
Meeting Abstract. 2022
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES
Yeoh, SE; (...); McMurray, JJAB -
Article. 10.1002/ejhf.2350. 2022
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
Wei, FF; (...); Staessen, JA
Article. 10.1038/s41440-024-01843-z. 2024
Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure
Vaduganathan, MM; (...); Solomon, SD
Article. 10.1002/ejhf.2635. 2022
Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure.
Vaduganathan, M; (...); Solomon, SD
Article. 2022
Effects of Triiodothyronine Treatment in an Animal Model of Heart Failure with Preserved Ejection Fraction
Neves, J.; (...); Leite Moreira, A.
Article. 10.1089/thy.2022.0717. 2023
Effects of Triiodothyronine Treatment in an Animal Model of Heart Failure with Preserved Ejection Fraction.
Neves, JS; (...); Leite Moreira, A
Article. 2023
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF
Dhingra, NK; (...); Packer, M
Article. 10.1016/j.jchf.2023.06.036. 2024
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF.
Dhingra, NK; (...); Packer, M
Article. 2024
Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial
Voors, AA; (...); Ponikowski, P
Meeting Abstract. 2021
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved
Coats, AJS; (...); Anker, SD
Article. 10.1002/jcsm.13393. 2024
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Anker, SD; (...); Zannad, F
Article. 10.1038/s41591-022-02041-5. 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
Anker, SD; (...); Zannad, F
Article. 2022
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Butler, J; (...); Zannad, F
Article. 10.1016/j.jacc.2023.03.390. 2023
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.
Butler, J; (...); Zannad, F
Article. 2023
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Balasubramanian, P; (...); Inzucchi, SE
Article. 10.1210/clinem/dgac154. 2022
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?.
Balasubramanian, P; (...); Inzucchi, SE
Article. 2022
Empagliflozin and Major Renal Outcomes in Heart Failure
Packer, M; (...); Anker, SD
Letter. 10.1056/NEJMc2112411. 2021
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis
Ferreira, JP; (...); Anker, S
Article. 10.1002/ejhf.3180. 2024
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
Ferreira, JP; (...); Packer, M
Article. 10.1093/eurheartj/ehac306. 2022
EMPAGLIFLOZIN AND SERUM POTASSIUM IN HEART FAILURE: AN ANALYSIS FROM EMPEROR-POOLED
Ferreira, JP
Meeting Abstract. 2022
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled ( ehac306, 2022)
Ferreira, JP; (...); Packer, M
Correction. 10.1093/eurheartj/ehac428. 2022
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
Ferreira, JP; (...); Packer, M
Article. 2022
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial
Ferreira, J.; (...); Zinman, B
Article. 10.1111/dom.14559. 2022
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
Ferreira, JP; (...); Zinman, B
Article. 2022
Empagliflozin benefits in patients with heart failure and preserved ejection fraction
Anker, SD; (...); Zannad, F
Editorial Material. 10.1038/s41591-022-02050-4. 2022
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
Filippatos, G; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.122.059785. 2022
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
Filippatos, G; (...); Anker, SD
Article. 2022
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Böhm, M; (...); Packer, M
Article. 10.1016/j.jacc.2021.07.049. 2021
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
Böhm, M; (...); Anker, SD
Article. 10.1016/j.jacc.2022.04.040. 2022
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
Böhm, M; (...); Anker, SD
Article. 2022
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled
Verma, S; (...); Packer, M
Letter. 10.1161/CIRCULATIONAHA.122.062644. 2023
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Anker, SD; (...); Packer, M
Article. 10.1056/NEJMoa2107038. 2021
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
Filippatos, G; (...); Anker, SD
Article. 10.1002/ejhf.2861. 2023
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
Filippatos, G; (...); Anker, SD
Article. 2023
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Verma, S; (...); Packer, M
Article. 10.1016/S2213-8587(21)00292-8. 2022
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Dhingra N.K.; (...); Lobo Márquez L.
Article. 2022
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Butler, J; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.121.057812. 2022
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Butler, J; (...); Anker, SD
Article. 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Böhm, M; (...); Butler, J
Article. 2022
Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes
Ribeiro, Eduarda; (...); Vale, Nuno
Article. 10.3390/jcm13144113. 2024
Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes.
Ribeiro, E; (...); Vale, N
Article. 2024
Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after catheter ablation
Cruz, I; (...); Fontes Carvalho, R.
Article. 10.1016/j.rec.2022.11.006. 2023
Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after catheter ablation.
Cruz, I; (...); Fontes-Carvalho, R
Article. 2023
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors
Marques, P; (...); Ferreira, JP
Article. 10.1002/ejhf.2992. 2023
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors.
Marques, P; (...); Ferreira, JP
Article. 2023
Exercise training counteracts the cardiac metabolic remodelling induced by experimental pulmonary arterial hypertension
Morais, F; (...); Moreira-Gonçalves, D
Article. 10.1016/j.abb.2022.109419. 2022
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial
Razaghizad, A; (...); Zannad, F
Article. 10.1111/dom.14867. 2023
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial.
Razaghizad, A; (...); Zannad, F
Article. 2023
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction An Exploratory Analysis of a Phase 3 Randomized Clinical Trial
Docherty, KF; (...); McMurray, JJV
Article. 10.1001/jamacardio.2021.2632. 2021
Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness
Bäck M.; (...); Rossignol P.
Article. 10.1093/ehjopen/oeac016. 2022
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
Ferreira, J.; (...); Leite Moreira, A.
Article. 10.2337/dc21-1977. 2022
Ferritin, inflammation, and iron deficiency in acute heart failure: evidence from the EDIFICA cohort
Vasques-Nóvoa F.; (...); Friões F.
Article. 10.1007/s00392-024-02535-x. 2024
FIB-4 Index should Guide the Referral of Patients with Metabolic Syndrome to Gastroenterology: The Perspective of a Portuguese Cohort
Borges-Canha, M; (...); Freitas, P
Article. 10.26497/ao230023. 2023
FIB-4 Index should Guide the Referral of Patients with Metabolic Syndrome to Gastroenterology: The Perspective of a Portuguese Cohort.
Borges Canha, M; (...); Freitas, P
Article. 2023
Flow-status and survival in severe aortic stenosis treated with TAVI - is flow rate superior to stroke volume index?
Santos Ferreira, D. A.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2022
Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies?
Lima T.; (...); Vitorino R.
Review. 10.1007/s11033-022-08207-1. 2023
Global longitudinal strain: Ready for prime time' in heart failure characterization
Donal, E, Neveu, A, Fontes-Carvalho, R
Editorial Material. 10.1002/ejhf.3012. 2023
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves, J.; (...); Md, JPF
Article. 10.1016/j.jacc.2023.05.048. 2023
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
Neves, JS; (...); Md, JPF
Article. 2023
Glucagon-like peptide 1 receptor agonists in heart failure: the need for a rewind
Ferreira, J., Neves, J.
Editorial Material. 10.1002/ejhf.2693. 2022
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials
Ferreira, J.; (...); Neves, J.
Article. 10.1111/dom.14997. 2023
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
Ferreira, JP; (...); Neves, JS
Article. 2023
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J.; (...); Neves, J.
Review. 10.1210/clinem/dgad398. 2023
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure.
Ferreira, JP; (...); Neves, JS
Review. 2023
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.3078. 2024
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program.
Ferreira, JP; (...); Zannad, F
Article. 2024
Health status across major subgroups of patients with heart failure and preserved ejection fraction
Siddiqi, TJ; (...); Butler, J
Article. 10.1002/ejhf.2831. 2023
Health status across major subgroups of patients with heart failure and preserved ejection fraction.
Siddiqi, TJ; (...); Butler, J
Article. 2023
Heart failure care: The time has come to tackle the cardiovascular "epidemic" of the XXI century
Santos-Ferreira, D, Fontes-Carvalho, R
Editorial Material. 10.1016/j.repc.2023.09.002. 2023
Heart Failure in Brazil and the Need to Measure and Take Action
Rivas-Lasarte, M, Ferreira, JP
Editorial Material. 10.1016/j.cardfail.2023.10.485. 2024
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
Böhm, M; (...); Anker, SD
Article. 10.1002/ejhf.2677. 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial.
Böhm, M; (...); Anker, SD
Article. 2022
Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure
Wei F.-F.; (...); Staessen J.A.
Article. 10.1002/ehf2.15000. 2024
Heterotopic Tricuspid Valve Implantation
Russo, G, Fontes Carvalho, R., Taramasso, M
Article. 10.1016/j.jaccas.2022.09.030. 2023
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial
Monzo, L; (...); Zannad, F
Article. 10.1016/j.cardfail.2023.11.020. 2024
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
Monzo, L; (...); Zannad, F
Article. 2024
High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.cardfail.2022.09.008. 2023
High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
Ferreira, JP; (...); Zannad, F
Article. 2023
High- versus low-dose losartan and uric acid: An analysis from HEAAL
Ferreira, JP; (...); Konstam, MA
Article. 10.1016/jucc.2023.04.005. 2023
High- versus low-dose losartan and uric acid: An analysis from HEAAL.
Ferreira, JP; (...); Konstam, MA
Article. 2023
Higher coronary artery calcium score is associated with increased risk of atrial fibrillation recurrence after catheter ablation
Fernandes, SL; (...); Fontes Carvalho, R.
Article. 10.1016/j.jcct.2022.10.002. 2023
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
Ferreira, JP; (...); Solomon, SD
Article. 10.1016/j.ijcard.2024.131818. 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.
Ferreira, JP; (...); Solomon, SD
Article. 2024
Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity
Ferreira, JP, Pitt, B, Zannad, F
Review. 10.1016/S2666-7568(21)00061-1. 2021
Home- versus centre-based EXercise InTervention in patients with Heart Failure (EXIT-HF trial): A pragmatic randomized controlled trial
Schmidt, C; (...); Santos, M
Article. 10.1016/j.repc.2023.05.013. 2024
Home- versus clinic-based exercise intervention in patients with heart failure (EXIT-HF trial): a pragmatic randomized controlled trial
Santos, M; (...); Ribeiro, F
Meeting Abstract. 2023
HUMAN IPSC ORGANOID PRODUCTION FOR PATIENT-SPECIFIC LIVER BIOFABRICATION
Martins-Santos, R; (...); Goldenberg, R
Meeting Abstract. 2023
Human-umbilical cord matrix mesenchymal cells improved left ventricular contractility independently of infarct size in swine myocardial infarction with reperfusion
Raposo, L; (...); Leite-Moreira, A
Article. 10.3389/fcvm.2023.1186574. 2023
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
Kasiakogias, A; (...); Kreutz, RAB -
Article. 10.1097/HJH.0000000000002910. 2021
Identification of sex-specific biomarkers predicting new-onset heart failure
Raafs, A; (...); Heymans, SAB -
Article. 10.1002/ehf2.13476. 2021
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced
Ferreira, JP; (...); Packer, M
Article. 10.1002/ejhf.2409. 2022
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
Ferreira, JP; (...); Packer, M
Article. 2022
Impact of cardiovascular risk factors in vascular remodelling of pregnant women
Ferreira, AF; (...); Falcao-Pires, I
Meeting Abstract. 2021
Impact of coronary artery calcium score screening on cardiovascular risk stratification of patients with atrial fibrillation undergoing ablation
Fernandes, S; (...); Ladeiras-Lopes, R
Article. 10.1159/000532018. 2023
Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients
Brandao, M; (...); Ferreira, JP
Article. 10.55563/clinexprheumatol/ua087b. 2023
Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients.
Brandão, M; (...); Ferreira, JP
Article. 2023
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
Khan, MS; (...); Packer, M
Article. 10.1161/JAHA.122.027652. 2023
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.
Khan, MS; (...); Packer, M
Article. 2023
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Biegus, J; (...); Ponikowski, P
Article. 10.1093/eurheartj/ehac530. 2023
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
Biegus, J; (...); Ponikowski, P
Article. 2023
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis
Talha, KM; (...); Packer, M
Article. 10.1111/dom.15572. 2024
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial
Ferreira, J.; (...); Zannad, F
Article. 10.1161/CIRCHEARTFAILURE.120.008075. 2021
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE
Dewan, P; (...); McMurray, JJV
Article. 10.1002/ejhf.2856. 2023
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
Dewan, P; (...); McMurray, JJV
Article. 2023
Impact of prediabetes in heart failure with preserved ejection fraction: the NetDiamond cohort
Borges-Canha, M; (...); Leite-Moreira, A
Meeting Abstract. 2021
Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort
Rastogi, T; (...); Ferreira, JP
Article. 10.1016/j.atherosclerosis.2022.02.017. 2022
Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort.
Rastogi, T; (...); Ferreira, JP
Article. 2022
Improved SWMM Modeling for Rapid Pipe Filling Incorporating Air Behavior in Intermittent Water Supply Systems
Ferreira, JP; (...); Kapelan, Z
Article. 10.1061/JHEND8.HYENG-13137. 2023
Improving risk stratification of moderate aortic stenosis
Teixeira, R.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
In Vitro Drug Repurposing: Focus on Vasodilators
Ribeiro, Eduarda; (...); Vale, Nuno
Review. 10.3390/cells12040671. 2023
Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials
Neves, J., Packer, M, Ferreira, J.
Article. 10.1016/j.cardfail.2023.03.017. 2023
Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials.
Neves, JS, Packer, M, Ferreira, JP
Article. 2023
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.2455. 2022
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Ferreira, JP; (...); Zannad, F
Article. 2022
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial
Packer, M; (...); Anker, SD
Letter. 10.1002/ejhf.2334. 2021
Influence of iron deficiency definition on the efficacy of intravenous iron in heart failure: a meta-analysis of randomized trials
Marques P.; (...); Ferreira J.P.
Article. 10.1007/s00392-024-02557-5. 2024
Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk
Ferreira, JP; (...); Rossignol, P
Letter. 10.1093/ckj/sfab246. 2022
Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury
Garcia, Bruno; (...); Herpain, Antoine
Article. 10.1186/s40635-024-00638-3. 2024
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme
Ferreira J.P.; (...); Januzzi J.L.
Article. 10.1002/ejhf.3227. 2024
Interaction of natriuretic peptide levels and ejection fraction on outcomes with dapagliflozin and empagliflozin in heart failure
Butler, J; (...); Packer, M
Letter. 10.1002/ejhf.2854. 2023
Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry
Vasques-Nóvoa, F; (...); Frioes, F
Article. 10.1016/j.cyto.2022.156053. 2022
Intracoronary imaging guided percutaneous coronary intervention of stent restenosis: does it make a difference?
Barradas, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Investigação Clínica da Iniciativa do Investigador em Portugal: Identificação de Problemas e Propostas para Melhoria. - Investigator-Led Clinical Research in PortugalProblem Identification and Proposals for Improvement.
Ferreira, JP; (...); Resende Oliveira, C
Article. 2023
Investigator-Led Clinical Research in Portugal: Problem Identification and Proposals for Improvement
Ferreira, JP; (...); Oliveira, CR
Article. 10.20344/amp.19333. 2023
Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?
Marques P., Sharma A., Ferreira J.P.
Editorial Material. 10.1016/j.jchf.2024.01.011. 2024
Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort
Monzo, L; (...); Rossignol, PAB -
Article. 10.1002/clc.23713. 2021
Ketones' impact on a dysmetabolic rat model of HFpEF
Goncalves, A; (...); Falcao-Pires, I
Meeting Abstract. 2023
Large animal models of pressure overload-induced cardiac left ventricular hypertrophy to study remodelling of the human heart with aortic stenosis
Beslika E.; (...); da Costa Martins P.A.
Article. 10.1093/cvr/cvae045. 2024
Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: Anti-AQP4 positive, anti-MOG positive and seronegative subgroups
Santos, E; (...); Sá, MJ
Article. 10.1016/j.msard.2022.103845. 2022
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction
Büttner P.; (...); Adams V.
Article. 10.1002/ehf2.15111. 2024
Left atrial strain evaluation to assess left ventricle diastolic dysfunction and heart failure with preserved ejection fraction: a guide to clinical practice Left atrial strain and diastolic function
Silva, MR; (...); Fontes Carvalho, R.
Article. 10.1007/s10554-023-02816-y. 2023
Letter of reply to the letter by Ryan
Ferreira, J.; (...); Neves, J.
Letter. 10.1111/dom.14743. 2022
Letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial
Ferreira, J., Neves, J.
Letter. 10.1002/ejhf.2694. 2022
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial
Böhm, M; (...); Anker, SD
Article. 10.1002/ejhf.2922. 2023
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial.
Böhm, M; (...); Anker, D
Article. 2023
Long-Term Exposure to Supraphysiological Levels of Testosterone Impacts Rat Submandibular Gland Proteome
Valente-Santos, J; (...); Amado, F
Article. 10.3390/ijms25010550. 2024
Long-term survival of female versus male patients after coronary artery bypass grafting
Abreu, A, Máximo, J, Leite-Moreira, A
Article. 10.1371/journal.pone.0275035. 2022
Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial
Cruz, M; (...); Pimenta, J
Article. 10.1007/s00392-023-02238-9. 2023
Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial.
Cruz, M; (...); Pimenta, J
Article. 2024
Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals
Kobayashi, M; (...); Girerd, N
Article. 10.1016/j.jcmg.2021.07.004. 2022
Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals.
Kobayashi, M; (...); Girerd, N
Article. 2022
Management of Heart Failure With Reduced Ejection Fraction in Patients With Diabetes Mellitus and Chronic Kidney Disease
Khan M.S.; (...); Butler J.
Review. 10.1016/j.semnephrol.2023.151429. 2023
Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial
Sharma, A; (...); Ferreira, JP
Meeting Abstract. 2021
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Zannad F.; (...); Harrison S.A.
Review. 10.1111/joim.13793. 2024
Mec?nica Ventricular Esquerda: Desvendando as Vias da Resposta Cardiovascular ao Exerc?cio
Vilela, EM, Fontes Carvalho, R.
Article. 10.36660/abc.20230181. 2023
Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort
Sharma, A; (...); Zannad, F
Article. 10.1159/000523717. 2022
Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort.
Sharma, A; (...); Zannad, F
Article. 2022
Metabolomics and Cardiovascular Risk in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Neves, LS; (...); Diaz, SO
Review. 10.3390/ijms25115693. 2024
Metformin Prevents Endothelial Dysfunction in Endometriosis through Downregulation of ET-1 and Upregulation of eNOS
Martins, AF; (...); Neves, D
Article. 10.3390/biomedicines10112782. 2022
Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials
Ferreira J.P.; (...); Neves J.S.
Article. 10.1159/000541686. 2024
Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients
Ferreira, JP, Rossello, X, Zannad, F
Editorial Material. 10.1002/ejhf.3098. 2023
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE
Ferreira, JP; (...); Voors, AA
Article. 10.1002/ejhf.2982. 2023
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
Ferreira, JP; (...); Voors, AA
Article. 2023
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
Ferreira, J.; (...); Anker, SD
Article. 10.1016/j.jacc.2022.01.029. 2022
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
Ferreira, JP; (...); Anker, SD
Article. 2022
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Ferreira, JP, Pitt, B, Zannad, F
Review. 10.1161/CIRCHEARTFAILURE.124.011629. 2024
Missed opportunities in the diagnosis of heart failure: a real-world assessment
Ferreira, JP; (...); Gavina, C
Article. 10.1002/ehf2.14531. 2023
Missed opportunities in the diagnosis of heart failure: a real-world assessment.
Ferreira, JP; (...); Gavina, C
Article. 2023
Mitochondrial remodeling underlying age-induced skeletal muscle wasting: let's talk about sex
Moreira-Pais A.; (...); Duarte J.A.
Article. 10.1016/j.freeradbiomed.2024.04.005. 2024
Modeling aortic stenosis progression: impact on follow-up, treatment and survival
Teixeira, R; (...); Fontes-Carvalho, R
Meeting Abstract. 2022
Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
Markousis-Mavrogenis, G; (...); van der Meer, P
Article. 10.1093/cvr/cvab235. 2022
Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
Markousis-Mavrogenis, G; (...); van der Meer, P
Article. 2022
Multiple versus single arterial grafting in the elderly: a meta-analysis of randomized controlled trials and propensity score studies
Saraiva, FA; (...); Leite Moreira, A.
Review. 10.23736/S0021-9509.21.11826-9. 2022
Myocardial deformation analysis using cardiac magnetic resonance in apical hypertrophic cardiomyopathy: is it an useful tool to predict adverse outcomes?
Fernandes, RM; (...); Fontes-Carvalho, R
Article. 10.1007/s10554-023-02902-1. 2023
Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock
Garcia, B; (...); Herpain, A
Article. 10.1186/s13054-022-04161-3. 2022
Myocardial phosphoproteomics and single cardiomyocyte force measurements endorse DYRK1A as a candidate therapeutic target for incomplete reverse remodelling after aortic valve replacement
Trindade, FF; (...); Falcao-Pires, I
Meeting Abstract. 2023
Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction
Inacio, JM; (...); Belo, JA
Article. 10.3390/biomedicines11082131. 2023
Myocardial stretch-induced compliance is abrogated under ischemic conditions and restored by cGMP/PKG-related pathways
Leite Moreira, AM; (...); Louren?o, A.
Article. 10.3389/fphys.2023.1271698. 2023
Myocardial stretch-induced compliance is abrogated under ischemic conditions and restored by cGMP/PKG-related pathways.
Leite Moreira, AM; (...); Lourenço, AP
Article. 2023
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction
Almeida-Coelho, J; (...); leite-moreira, af
Letter. 10.1161/CIRCHEARTFAILURE.124.011833. 2024
National registries for rare clinical conditions: Networking to promote evidence-based healthcare
Leite-Moreira, AF, Saraiva, F
Editorial Material. 10.1016/j.repc.2023.03.007. 2023
Neuromyelitis optica spectrum disorders: A nationwide Portuguese clinical epidemiological study
Santos, E; (...); Sá, MJ
Article. 10.1016/j.msard.2021.103258. 2021
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial
Ferreira, J.; (...); Zannad, FAB -
Article. 10.1007/s00392-021-01891-2. 2022
No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial
Ferreira, JP; (...); Zannad, F
Letter. 10.1016/j.acvd.2021.10.003. 2021
Noblestitch Failure After Percutaneous Patent Foramen Ovale Closure in a Case Of Platypnea-Orthodeoxia Syndrome: Is this Device Suitable for All Patients?
Moura, AR; (...); Fontes Carvalho, R.
Article. 10.36660/abcimg.2022309i. 2023
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial
Pocock, SJ; (...); Packer, M
Article. 10.1093/eurheartj/ehab579. 2021
Nuclear tension controls mitotic entry by regulating cyclin B1 nuclear translocation
Dantas, M; (...); Ferreira, J.
Article. 10.1083/jcb.202205051. 2022
Obituary: Paulo Bettencourt 1965-2021
Lourenço, P; (...); Ferreira, AL
Biographical-Item. 10.1002/ejhf.2359. 2021
Office- versus home-based evaluation of quality of life in heart failure with reduced ejection fraction: A randomized study
de Almeida Pinho I.; (...); Ferreira J.P.
Article. 10.1016/j.ijcard.2024.132341. 2024
Off-pump versus on-pump coronary artery bypass grafting: a propensity score-matching analysis of safety and long-term results
Saraiva, FA; (...); Leite-Moreira, AF
Meeting Abstract. 2021
Omecamtiv Mecarbil A Personalized Treatment for Patients With Severely Impaired Ejection Fraction
Ferreira, J.AB -
Editorial Material. 10.1016/j.jacc.2021.04.077. 2021
On the Impact of Synchronous Electrocardiogram Signals for Heart Sounds Segmentation
Silva, A; (...); Renna, F
Proceedings Paper. 10.1109/EMBC40787.2023.10341149. 2023
One more piece in the puzzle of stem cell therapy in cardiovascular diseases;
Nogueira-Ferreira R., Leite-Moreira A.F.
Note. 10.1016/j.repc.2024.08.007. 2024
Optimization of a Protocol for Protein Extraction from Calcified Aortic Valves for Proteomics Applications: Development of a Standard Operating Procedure
Trindade, F; (...); Vitorino, R
Article. 10.3390/proteomes10030030. 2022
Optimization of a Protocol for Protein Extraction from Calcified Aortic Valves for Proteomics Applications: Development of a Standard Operating Procedure.
Trindade, F; (...); Vitorino, R
Article. 2022
Optimizing heart failure pathways to enhance patient care: the Program to Optimize Heart Failure Patient Pathways (PRO-HF)
Patwala, Ashish; (...); Mebazaa, Alexandre
Article. 10.1002/ehf2.14911. 2024
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions
Anker, SD; (...); Butler, J
Article. 10.1002/ejhf.2558. 2022
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions.
Anker, SD; (...); Butler, J
Article. 2022
Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT
Ferreira, J.; (...); Zannad, FAB -
Article. 10.1002/ejhf.2376. 2022
Pathophysiological and therapeutic implications of urocortin-2 in heart failure with preserved ejection fraction
Adao, R; (...); Bras-Silva, C
Meeting Abstract. 2022
Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial
Razaghizad, A; (...); Sharma, A
Article. 10.1016/j.cardfail.2023.10.474. 2024
Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial.
Razaghizad, A; (...); Sharma, A
Article. 2024
Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia
Ferreira J.P.
Editorial Material. 10.1016/j.jchf.2024.07.020. 2024
Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
Kobayashi, M; (...); Ferreira, J.AB -
Article. 10.1002/clc.23576. 2021
Pericardial Fluid Accumulates microRNAs That Regulate Heart Fibrosis after Myocardial Infarction
Silva, ED; (...); Nascimento, DS
Article. 10.3390/ijms25158329. 2024
Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.
Santos Ferreira, D; (...); Zannad, F
Article. 2024
Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design - A population-based study
Baptista, R; (...); Gavina, C.
Article. 10.1016/j.repc.2023.10.004. 2023
Predictive Risk Score for Acute Kidney Injury in Hematopoietic Stem Cell Transplant
Rodrigues, N; (...); Lopes, JA
Article. 10.3390/cancers15143720. 2023
Predictors for NYHA recovery and 1-year mortality after mitral TEER
Santos Ferreira, D. A.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2022
Predictors of AF recurrence in patients with paroxysmal AF undergoing catheter ablation: new predictors coming?
Ribeiro Silva, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2022
Predictors of left ventricular dysfunction in hypertrophic cardiomyopathy: results from a nationwide registry
Brandao, M.; (...); Portuguese Registry Hypertrophic
Meeting Abstract. 2022
Predictors of mortality in patients with advanced heart failure and cardiac resynchronization therapy
Brochado, L.; (...); Leite-Moreira, A.
Meeting Abstract. 2023
Preoperative smoking status and long-term survival after coronary artery bypass grafting: a competing risk analysis
Abreu A., Máximo J.D., Leite-Moreira A.
Article. 10.1093/ejcts/ezae183. 2024
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled
Verma, S; (...); Packer, M
Letter. 10.1161/ATVBAHA.123.319156. 2023
Prognostic association of circulating relaxin-2 in acute heart failure
Pintalhao M.; (...); Castro-Chaves P.
Article. 10.1016/j.ijcard.2024.132358. 2024
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
Januzzi, JL; (...); Anker, SD
Article. 10.1016/j.jchf.2022.05.004. 2022
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
Januzzi, JL; (...); Anker, SD
Article. 2022
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Januzzi, JL; (...); Packer, M
Article. 10.1016/j.jacc.2021.07.046. 2021
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial
Martens, P; (...); Rossignol, P
Article. 10.1093/ehjacc/zuab111. 2022
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.
Martens, P; (...); Rossignol, P
Article. 2022
Prognostic value of flow-status in severe aortic stenosis patients undergoing percutaneous intervention
Santos-Ferreira, D; (...); Fontes-Carvalho, R
Article. 10.1007/s10554-023-02992-x. 2023
Prognostic value of flow-status in severe aortic stenosis patients undergoing percutaneous intervention.
Santos Ferreira, D; (...); Fontes Carvalho, R
Article. 2024
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study
Girerd, N; (...); Zannad, F
Article. 10.1161/CIRCHEARTFAILURE.122.009694. 2023
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study.
Girerd, N; (...); Zannad, F
Article. 2023
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
Verdonschot, JAJ; (...); Heymans, SRB
Article. 10.1186/s12933-021-01357-9. 2021
Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort
Kobayashi M.; (...); Girerd N.
Article. 10.1002/ejhf.3202. 2024
Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there
Zannad F., Ferreira J.P.
Editorial Material. 10.1093/eurheartj/ehae399. 2024
Quality of life after pulmonary veins isolation: outcomes from a digital follow-up program
Teixeira, R.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire
Ravera, A; (...); Voors, AAAB -
Article. 10.1002/ejhf.2154. 2021
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program
Packer M.; (...); Zannad F.
Article. 10.1016/j.jacc.2024.07.013. 2024
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin An EMPEROR-Pooled Analysis
Ferreira, JP; (...); Packer, M
Article. 10.1016/j.jchf.2023.01.018. 2023
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin An EMPEROR-Pooled Analysis.
Ferreira, JP; (...); Packer, M
Article. 2023
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure
Ferreira, J.; (...); Zannad, F
Editorial Material. 10.1002/ejhf.2457. 2022
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Lam, CSP; (...); Packer, M
Article. 10.1093/eurheartj/ehab360. 2021
Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort
Pintalhao, M; (...); Leite Moreira, A.
Article. 10.1016/j.ijcard.2022.07.037. 2022
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
Voors, AA; (...); Ponikowski, P
Article. 10.1002/ejhf.2681. 2022
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Voors, AA; (...); Ponikowski, P
Article. 2022
Reply to 'Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?'
Ferreira, JP, Voors, AA
Editorial Material. 10.1002/ejhf.3415. 2024
Reply to Letter to the Editor regarding the article ?Suboptimal control of cardiovascular risk factors in myocardial infarction survivors in a cardiac rehabilitation program?
Silva, V; (...); Fontes-Carvalho, R
Article. 10.1016/j.repc.2022.10.006. 2022
Reply to the letter entitled “Inflammation in Heart Failure with Preserved Ejection Fraction: A Bystander or A Participant?” by Zhong M and Yan X
Ferreira J.P., Zannad F., Solomon S.D.
Letter. 10.1016/j.ijcard.2024.132278. 2024
Representativeness of EXPLORER-HCM trial and prevalence of eligibility criteria for Mavacamten in a nationwide cohort
Brandao, M.; (...); Portuguese Registry Hypertrophic
Meeting Abstract. 2022
Response and long-term outcomes with resynchronization therapy: the role of heart failure etiology
Brandao, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2022
Response to Letter to Editor From Banerjee et al: "Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure"
Ferreira, JP, Neves, JS
Letter. 10.1210/clinem/dgad507. 2023
Resposta da Press?o Arterial e Ecocardiografia sob Estresse F?sico: Novas Perspectivas sobre um Desafio Contempor?neo
Vilela, EM, Fontes Carvalho, R.
Article. 10.36660/abc.20230737. 2023
RETRACTED: Valve-in-valve TAVI for treatment of degenerated surgical aortic bioprosthesis (Retracted article. See vol. 119, 2023)
Silva, Mariana Ribeiro; (...); Fontes-Carvalho, Ricardo
Meeting Abstract. 10.1093/cvr/cvac157.020. 2022
RETRACTED: Vascular access computed tomography angiography-derived iliofemoral calcium volume in the evaluation of vascular and bleeding complications after transfemoral TAVI (Retracted article. See vol. 119, 2023)
Silva, Mariana Ribeiro; (...); Fontes-Carvalho, Ricardo
Meeting Abstract. 10.1093/cvr/cvac157.075. 2022
Retrieval of a dislodged stent during transcatheter aortic valve replacement
Silva, MR; (...); Fontes Carvalho, R.
Article. 10.1007/s12928-023-00913-2. 2023
Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis
Sousa Nunes F.; (...); Sousa C.
Review. 10.3389/fcvm.2024.1407566. 2024
Reverse Translation of Pericardial Access: Pericardial Catheter Implantation in Mice
Mendes-Ferreira P., Leite-Moreira A.M., Leite-Moreira A.F.
Editorial Material. 10.1016/j.jacbts.2024.08.007. 2024
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
Neves, J.; (...); Ferreira, J.
Article. 10.1111/dom.14862. 2023
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.
Neves, JS; (...); Ferreira, JP
Article. 2023
Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France
Baudry, G; (...); Girerd, N
Article. 10.1002/ejhf.3103. 2023
Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France.
Baudry, G; (...); Girerd, N
Article. 2023
Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study
Monzo L.; (...); Girerd N.
Article. 10.1002/ejhf.2986. 2023
Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study.
Monzo, L; (...); Girerd, N
Article. 2023
Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal
Santos, M; (...); de Sá, J
Review. 10.1097/WNF.0000000000000552. 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction A Post Hoc Analysis of the EMPEROR-Preserved Trial
Butler, J; (...); Anker, S
Article. 10.1001/jamacardio.2023.1090. 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction. - A Post Hoc Analysis of the EMPEROR-Preserved Trial.
Butler, J; (...); Anker, S
Article. 2023
Sarcopenia as a Prognostic Factor in Peripheral Arterial Disease: Descriptive Review
Ferreira, J.; (...); Correia Neves, M
Article. 10.1016/j.avsg.2021.01.076. 2021
Semaglutide and Cardiovascular Outcomes
Neves, JS, Leite, AR, Ferreira, JP
Letter. 10.1056/NEJMc2400414. 2024
Sex differences and survival after TAVI for severe aortic stenosis
Ferreira, D. A. Santos; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Sex differences in aortic stenosis progression and myocardial response
Teixeira, R.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Sex differences in circulating proteins of patients with rheumatoid arthritis: A cohort study
Ferreira, MB; (...); Ferreira, JP
Article. 10.1111/1756-185X.14323. 2022
Sex differences in circulating proteins of patients with rheumatoid arthritis: A cohort study.
Ferreira, MB; (...); Ferreira, JP
Article. 2022
Sex-based differences and risk of recurrence in patients with atrial fibrillation undergoing pulmonary vein isolation
Aguiar-Neves, Ines; (...); Fontes-Carvalho, Ricardo
Article. 10.1016/j.ijcard.2024.132161. 2024
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier
Aguiar-Neves, I, Santos-Ferreira, D, Fontes-Carvalho, R
Article. 10.31083/j.rcm2401001. 2023
Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?
Neves J.S.; (...); Ferreira J.P.
Article. 10.1016/j.jacc.2024.06.026. 2024
Sixty years of the Bruce protocol: reappraising the contemporary role of exercise stress testing with electrocardiographic monitoring
Vilela, EM; (...); Fontes Carvalho, R.
Article. 10.1097/j.pbj.0000000000000235. 2023
Size does matter: a simple swine model of chronic pulmonary hypertension
Moreira-Costa, L; (...); Mendes-Ferreira, P
Meeting Abstract. 10.1183/13993003.congress-2023.PA440. 2023
Social media use by cardiovascular healthcare professionals in Portugal
Esteves-Pereira, M; (...); Ladeiras-Lopes, R
Article. 10.1016/j.repc.2022.03.010. 2023
Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations
Butler, J; (...); Packer, MAB -
Editorial Material. 10.1093/eurheartj/ehab704. 2021
Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis
Ferreira, JP; (...); Leite-Moreira, A
Article. 10.1530/EJE-20-1484. 2021
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.2726. 2023
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira, JP; (...); Zannad, F
Article. 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials
Ferreirra, JP; (...); Zannad, F
Article. 10.1016/j.ijcard.2023.01.088. 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Ferreira, JP; (...); Zannad, F
Article. 2023
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial
Ferreira, J.; (...); Zannad, F
Article. 10.1093/ehjcvp/pvab031. 2022
Staging cardiac damage in patients with aortic regurgitation
Silva, G; (...); Sampaio, F
Article. 10.1007/s10554-022-02673-1. 2022
Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study
Roncon Albuquerque, R.; (...); Paiva, J.
Article. 10.1186/s13613-023-01185-y. 2023
Steroidal MRA Across the Spectrum of Renal Function
Ferreira, JP; (...); Rossignol, P
Article. 10.1016/j.jchf.2022.06.010. 2022
Steroidal MRA Across the Spectrum of Renal Function.
Ferreira, JP; (...); Rossignol, P
Article. 2022
Stretch-induced compliance mechanism in pregnancy-induced cardiac hypertrophy and the impact of cardiovascular risk factors
Ferreira A.F.; (...); Falcão-Pires I.
Article. 10.1152/ajpheart.00701.2023. 2024
Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort
Alexandre A.; (...); Rodrigues P.
Article. 10.1007/s00392-024-02548-6. 2024
Subclinical Thyroid Dysfunction and Cardiovascular Disease
Lourenco, IM; (...); Neves, JS
Review. 10.26497/ar230029. 2023
Subclinical Thyroid Dysfunction and Cardiovascular Disease.
Lourenco, IM; (...); Neves, JS
Review. 2023
Synchronous spontaneous coronary artery dissection after pregnancy: when the two happen at once
Silva, G; (...); Fontes Carvalho, R.
Article. 10.1097/mca.0000000000001172. 2023
TARGETING PREMATURE AGING TO IMPROVE HFPEF
Silva, E. D.; (...); Nascimento, D. S.
Meeting Abstract. 2023
The additive effects of anaemia and transfusion on long-term survival after coronary artery bypass surgery
Abreu A.; (...); Leite-Moreira A.
Article. 10.1093/ejcts/ezad403. 2024
The additive role of cardiac CT in a patient with cardiogenic shock and suspected mechanical complication of myocardial infarction
Temtem, M; (...); Fontes-Carvalho, R
Editorial Material. 10.1093/ehjci/jead066. 2023
The Association between Gestational Diabetes and the Microbiome: A Systematic Review and Meta-Analysis
Teixeira, RA; (...); Barros, A.
Review. 10.3390/microorganisms11071749. 2023
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial
Kobayashi, M; (...); Zannad, F
Article. 10.1002/ejhf.2579. 2022
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Kobayashi, M; (...); Zannad, F
Article. 2022
The Best Articles of 2022 in the Arquivos Brasileiros de Cardiologia and Revista Portuguesa de Cardiologia
de Oliveira, GMM; (...); Rochitte, CE
Review. 10.36660/abc.20230342. 2023
The best articles of 2022 in the Arquivos Brasileiros de Cardiologia and Revista Portuguesa de Cardiologia
de Oliveira G.M.M.; (...); Rochitte C.E.
Article. 10.1016/j.repc.2023.10.001. 2023
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
Verdonschot, JAJ; (...); Heymans, SRB
Article. 10.1016/j.cardfail.2021.12.005. 2022
The Effect of the Stress Induced by Hydrogen Peroxide and Corticosterone on Tryptophan Metabolism, Using Human Neuroblastoma Cell Line (SH-SY5Y).
Correia, AS; (...); Vale, N
Article. 2023
The extent of postpartum cardiac reverse remodeling is reflected in urine proteome
Ferreira A.F.; (...); Barros A.S.
Article. 10.1038/s41598-024-65612-1. 2024
The Future of Meat. Health Impact Assessment with Randomized Evidence
Ferreira, J., Sharma, A, Zannad, FAB -
Review. 10.1016/j.amjmed.2020.11.007. 2021
The Heart as a ?Balance? in Everyday and After Life: Lessons From Ancient Egypt
Vilela, E, Fontes Carvalho, R.
Article. 10.1016/j.jaccas.2023.102010. 2023
The impact of echocardiographic indexation to evaluate cardiac reverse remodeling throughout pregnancy and postpartum
Ferreira, AF; (...); Falcao-Pires, I
Article. 10.1016/j.repc.2023.04.014. 2024
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes A Meta-Analysis of Randomized Placebo-Controlled Trials
Mendonça, L; (...); Ferreira, JP
Article. 10.2215/CJN.0000000584. 2024
The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
Leite, M; (...); Fontes Carvalho, R
Article. 2023
The impact of pre-existing right bundle brunch block on short and mid-term outcomes after transcatheter aortic valve implantation
Silva, Mariana Ribeiro; (...); Fontes-Carvalho, Ricardo
Meeting Abstract. 2022
The PERInatal MYocardial Remodeling (PERIMYR) cohort study protocol: A prospective study of cardiac remodeling and "recovery" in pregnancy as a model to understand the impact of comorbidities in cardiac remodeling and reverse remodeling
Ferreira, AF; (...); Falcao-Pires, I
Article. 10.1016/j.repc.2022.08.015. 2023
The SAFEST study: The crucial role of primary health care in the diagnosis and management of atrial fibrillation
Gon?alves-Teixeira, P; (...); Fontes Carvalho, R.
Article. 10.1016/j.repc.2023.04.015. 2024
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Voors, AA; (...); Ponikowski, P
Article. 10.1038/s41591-021-01659-1. 2022
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors, AA; (...); Ponikowski, P
Article. 2022
The Use of Radiomic Analysis in Cardiovascular Diseases.
Vieira Santos-Silva M; (...); Dias-Neto M
Article. 10.48729/pjctvs.286. 2022
The win ratio in cardiology trials: lessons learnt, new developments, and wise future use
Pocock, SJ; (...); Stone, GW
Review. 10.1093/eurheartj/ehae647. 2024
The win ratio method in heart failure trials: lessons learnt from EMPULSE
Pocock, SJ; (...); Voors, AA
Article. 10.1002/ejhf.2853. 2023
The win ratio method in heart failure trials: lessons learnt from EMPULSE.
Pocock, SJ; (...); Voors, AA
Article. 2023
The year 2021 in the European Heart Journal-Cardiovascular Imaging: Part I
Edvardsen, T; (...); Cosyns, B
Article. 10.1093/ehjci/jeac210. 2022
Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization
Henry, A; (...); Lumbers, RT
Article. 10.1161/CIRCULATIONAHA.121.056663. 2022
Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.
Henry, A; (...); Lumbers, RT
Article. 2022
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE
Ferreira, JP; (...); Voors, AA
Article. 10.1002/ejhf.3369. 2024
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial
Monzo, L; (...); Zannad, F
Article. 10.1002/ejhf.2952. 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial.
Monzo, L; (...); Zannad, F
Article. 2023
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
Bedrouni, W; (...); Zannad, F
Letter. 10.1161/CIRCHEARTFAILURE.121.009295. 2022
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial
Tromp J.; (...); Voors A.A.
Article. 10.1002/ejhf.3218. 2024
Ulcerated Gastric Lipoma Presenting with Gastrointestinal Bleeding and Hypovolemic Shock
Ferreira, J., Santos, A, Germano, A
Article. 10.5334/jbsr.2700. 2022
Unraveling the Impact of miR-146a in Pulmonary Arterial Hypertension Pathophysiology and Right Ventricular Function
Santos-Gomes, J; (...); Brás-Silva, C
Article. 10.3390/ijms25158054. 2024
Unravelling the Gut Microbiome Role in Cardiovascular Disease: A Systematic Review and a Meta-Analysis
Martins, D; (...); Miranda, IM
Review. 10.3390/biom14060731. 2024
Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signatures
Ferreira, MB; (...); Ferreira, JP
Article. 10.1080/03009742.2023.2196781. 2023
Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signatures.
Ferreira, MB; (...); Ferreira, JP
Article. 2023
Unveiling Human Proteome Signatures of Heart Failure with Preserved Ejection Fraction
Sebastiao, MJ; (...); Gomes-Alves, P
Article. 10.3390/biomedicines10112943. 2022
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Doehner W.; (...); Packer M.
Article. 10.1016/j.jchf.2024.08.020. 2024
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
Doehner, W; (...); Packer, M
Article. 10.1093/eurheartj/ehac320. 2022
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Doehner, W; (...); Packer, M
Article. 2022
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Yu, YL; (...); Staessen, JA
Article. 10.1136/heartjnl-2023-323796. 2024
Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance
Ferreira, JP; (...); Franco, F
Article. 10.1002/ehf2.14090. 2022
Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
Ferreira, JP; (...); Franco, F
Article. 2022
Value of cardiac magnetic resonance on the risk stratification of cardiomyopathies
Vidal-Perez, R; (...); Vazquez-Rodriguez, JM
Review. 10.4330/wjc.v15.i10.487. 2023
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
Khan, MS; (...); Butler, J
Article. 10.1016/j.cardfail.2023.06.024. 2023
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.
KHAN, MS; (...); BUTLER, J
Article. 2023
Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up
Kanbay, M; (...); Rossignol, P
Article. 10.1161/JAHA.121.023301. 2022
Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up.
Kanbay, M; (...); Rossignol, P
Article. 2022
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced
Anker, SD; (...); Packer, M
Article. 10.1002/ejhf.2728. 2023
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.
Anker, SD; (...); Packer, M
Article. 2023
Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT
Ferreira, J.; (...); Zannad, F
Article. 10.1007/s00392-021-01962-4. 2022
Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT.
Ferreira, JP; (...); Zannad, F
Article. 2022
Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI
Pitt, B, Ferreira, J., Zannad, F
Editorial Material. 10.1093/eurheartj/ehab717. 2022
winratiotest: A command for implementing the win ratio and stratified win ratio in Stata
Gregson J., Ferreira J.P., Collier T.
Article. 10.1177/1536867X231196480. 2023
winratiotest: A command for implementing the win ratio and stratified win ratio in Stata.
Gregson, J, Ferreira, JP, Collier, T
Article. 2023
Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings
Ferreira, JP; (...); McMurray, JJV
Article. 10.1002/ehf2.13731. 2022
Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings.
Ferreira, JP; (...); McMurray, JJ
Article. 2022
Aortic Valve Surgery With Stented Versus Stentless Bioprosthesis In Patients With Active Infective Endocarditis
Projeto de fim de curso
Colaboradores: Joaquim Adelino Correia Ferreira Leite Moreira
Freedom And Smart Solo Stentless Bioprosthesis For Aortic Valve Replacement - Clinical And Hemodynamic Evaluation-Systematic Review And Meta-Analysis
Projeto de fim de curso
Colaboradores: Francisca Almeida Saraiva
